通过迷宫精确导航:克服非小细胞肺癌中的EGFR耐药性
Junhui Wang1, Jian Wang2, Jianxin Chen3
1Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.
Annals of medicine
|October 15, 2025
概括
皮表皮生长因子受体 (EGFR) 和氨酸激酶抑制剂 (TKI) 耐药性是非小细胞肺癌 (NSCLC) 治疗的一个主要挑战. 了解耐药机制和开发新疗法是改善患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI) 已经改变了非小细胞肺癌 (NSCLC) 治疗方法.
- 对EGFRTKI的治疗耐药性显著限制了它们在NSCLC患者的长期有效性.
研究的目的:
- 提供EGFR TKI在NSCLC中的耐药性机制的全面审查.
- 探索不断发展的治疗对策和诊断技术,以管理耐药性.
- 检查用于克服耐药性的新药和组合疗法.
主要方法:
- 对抗性机制,诊断方法和治疗策略的文献综述.
- 抵抗机制的分类,包括目标,绕道通路,组织学转换和代谢重编程.
- 评估综合诊断技术,如多维活检和多omics分析.
主要成果:
- 关于NSCLC中EGFR TKI耐药机制的详细地图,根据临床相关性进行分类.
- 评估用于检测耐药性改变的诊断工具,例如C797S突变.
- 新兴疗法的概述,包括第四代TKI,抗体-药物联合体 (ADC) 和组合策略.
结论:
- 深入了解EGFR耐药性对于改善NSCLC患者预后至关重要.
- 通过新型药物和组合策略来完善治疗范式是必不可少的.
- 解决耐药性管理方面的挑战,包括毒性和未解决的科学问题,至关重要.
关键词:
这是C797S突变.皮表皮肤生长因子受体 (EGFR)在MET中放大放大功率.非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.精准医学是一门精准的医学.循环瘤DNA (ctDNA) 的发生.组合疗法治疗组合治疗.电阻机制的阻力机制.有针对性的治疗.氨酸激酶抑制剂 (TKI) 耐药性更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
相关概念视频
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K